应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01801 信达生物
已收盘 09-19 16:08:11
42.150
-1.650
-3.77%
最高
44.650
最低
41.500
成交量
1,067万
今开
43.850
昨收
43.800
日振幅
7.19%
总市值
687.49亿
流通市值
687.49亿
总股本
16.31亿
成交额
4.53亿
换手率
0.65%
流通股本
16.31亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
异动解读 | 机构减持是主因 信达生物股价大跌5%
异动解读 · 14:52
异动解读 | 机构减持是主因 信达生物股价大跌5%
【港股通】信达生物(01801)跌4% 此前遭摩通减持1,553.61万股
金吾财讯 · 14:37
【港股通】信达生物(01801)跌4% 此前遭摩通减持1,553.61万股
信达生物(01801)下跌5.02%，报41.6元/股
金融界 · 13:32
信达生物(01801)下跌5.02%，报41.6元/股
信达生物盘中异动 下午盘快速下跌5.02%
市场透视 · 13:32
信达生物盘中异动 下午盘快速下跌5.02%
信达生物在2024年欧洲肿瘤内科学会（ESMO）大会公布全球首创PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363联合贝伐珠单抗治疗晚期结直肠癌的临床I期数据
美通社 · 09-18 08:00
信达生物在2024年欧洲肿瘤内科学会（ESMO）大会公布全球首创PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363联合贝伐珠单抗治疗晚期结直肠癌的临床I期数据
信达生物在2024年欧洲肿瘤内科学会（ESMO）大会口头报告抗HER2单克隆抗体-喜树碱衍生物偶联物（HER2 ADC）IBI354治疗晚期卵巢癌、乳腺癌等实体瘤的临床数据
美通社 · 09-18 08:00
信达生物在2024年欧洲肿瘤内科学会（ESMO）大会口头报告抗HER2单克隆抗体-喜树碱衍生物偶联物（HER2 ADC）IBI354治疗晚期卵巢癌、乳腺癌等实体瘤的临床数据
小摩减持信达生物(01801)约1553.61万股 每股作价约43.05港元
智通财经 · 09-17 19:54
小摩减持信达生物(01801)约1553.61万股 每股作价约43.05港元
【券商聚焦】汇丰研究升信达生物(01801)目标价5.45% 指上半年收入胜预期
金吾财讯 · 09-17 16:47
【券商聚焦】汇丰研究升信达生物(01801)目标价5.45% 指上半年收入胜预期
汇丰研究升信达生物目标价至58港元 上半年收入胜预期
美港电讯 · 09-16
汇丰研究升信达生物目标价至58港元 上半年收入胜预期
《大行》汇丰研究升信达生物(01801.HK)目标价至58元 上半年收入胜预期
阿斯达克财经 · 09-16
《大行》汇丰研究升信达生物(01801.HK)目标价至58元 上半年收入胜预期
信达生物(1801.HK)：亮相ESMO&WCLC大会 PD-1&IL2Α疗效出色
中信建投证券 · 09-14
信达生物(1801.HK)：亮相ESMO&WCLC大会 PD-1&IL2Α疗效出色
信达生物(01801)上涨2.44%，报44.0元/股
金融界 · 09-13
信达生物(01801)上涨2.44%，报44.0元/股
医药创新支持力度加大 创新药板块集体上行 中国生物制药(01177)涨4.5%
金吾财讯 · 09-13
医药创新支持力度加大 创新药板块集体上行 中国生物制药(01177)涨4.5%
花旗：对信达生物开启90天上行催化剂观察期 目标价62港元
新浪港股 · 09-12
花旗：对信达生物开启90天上行催化剂观察期 目标价62港元
信达生物现涨超4% 玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告
新浪港股 · 09-12
信达生物现涨超4% 玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告
生物制药板块走势强劲 科伦博泰生物(06990)涨6.6% 机构指创新药企业盈亏平衡点渐近
金吾财讯 · 09-12
生物制药板块走势强劲 科伦博泰生物(06990)涨6.6% 机构指创新药企业盈亏平衡点渐近
港股异动 | 信达生物(01801)涨超4% 玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告
智通财经 · 09-12
港股异动 | 信达生物(01801)涨超4% 玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告
花旗：对信达生物(01801)开启90天上行催化剂观察期 目标价62港元
智通财经 · 09-12
花旗：对信达生物(01801)开启90天上行催化剂观察期 目标价62港元
《大行》花旗对信达生物(01801.HK)开启90天上行催化剂观察期
阿斯达克财经 · 09-12
《大行》花旗对信达生物(01801.HK)开启90天上行催化剂观察期
头对头优效于高剂量度拉糖肽，玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告
美通社 · 09-12
头对头优效于高剂量度拉糖肽，玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告
加载更多
公司概况
公司名称：
信达生物
所属市场：
SEHK
上市日期：
--
主营业务：
信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销，以及提供咨询及研发服务。该公司的主要产品为达伯舒（信迪利单抗注射液），用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303，用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305，用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌（NSCLC）。利妥昔单抗生物类似药IBI-301，用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。
发行价格：
--
{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":42.15,"timestamp":1726733291013,"preClose":43.8,"halted":0,"volume":10674404,"delay":0,"floatShares":1631045869,"shares":1631045869,"eps":-0.7272389,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.65,"latestTime":"09-19 16:08:11","open":43.85,"high":44.65,"low":41.5,"amount":453223141,"amplitude":0.071918,"askPrice":42.15,"askSize":14000,"bidPrice":42.05,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":-0.8818272673851381,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1726795800000},"adr":0,"listingDate":1540915200000,"adjPreClose":43.8,"openAndCloseTimeList":[[1726709400000,1726718400000],[1726722000000,1726732800000]],"volumeRatio":2.201219,"impliedVol":0.4644,"impliedVolPercentile":0.1093,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK"},"requestUrl":"/m/hq/s/01801/","defaultTab":"news","newsList":[{"id":"1159320559","title":"异动解读 | 机构减持是主因 信达生物股价大跌5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159320559","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159320559?lang=zh_cn&edition=full","pubTime":"2024-09-19 14:52","pubTimestamp":1726728767,"startTime":"0","endTime":"0","summary":"信达生物(01801)今日在港股市场表现低迷,股价盘中一度大跌逾5%。分析人士指出,这主要受到此前机构投资者大笔减持该股影响。\n\n根据香港联交所9月17日披露的文件,摩根大通于9月11日场内场外合计以每股约43港元的价格减持了信达生物约1,553万股,占公司总股本约0.95%。减持后,摩根大通持股比例下降至5.38%。\n\n除了机构减持外,信达生物股价大跌的具体原因暂时不得而知。但外资大举抛售无疑加剧了投资者对该股的担忧情绪,推动了今日的跳水行情。专家建议,投资者可以继续观察信达生物后续的公告和业绩表现,以判断这一跌势是否将持续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01801"],"gpt_icon":0},{"id":"2468176543","title":"【港股通】信达生物(01801)跌4% 此前遭摩通减持1,553.61万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2468176543","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468176543?lang=zh_cn&edition=full","pubTime":"2024-09-19 14:37","pubTimestamp":1726727860,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达生物(01801)股价疲软，午后跌幅加剧，截至发稿，报42.05港元，跌4%，成交额3.57亿港元。根据香港联交所9月17日披露的文件，摩根大通(JPMorgan Chase & Co.)于9月11日以场内每股均价43.0477港元，场外每股均价42.9027港元合计售出信达生物1,553.61万股普通股股份，价值约6.69亿港元。售出后，摩根大通最新持股数目为8,780.56万股股份，好仓比例由6.33%降至5.38%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NDg0MDg1OTU1MTI3MjAzNTczNjYwMTQ3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NDg0MDg1OTU1MTI3MjAzNTczNjYwMTQ3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1944502","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550221.USD","IE00BHPRN162.USD","IE00BKVL7J92.USD","HSTECH","LU0323591593.USD","BK4566","LU0215105999.USD","IE00B3S45H60.SGD","IE00BBT3K403.USD","LU0170899867.USD","LU1119994496.HKD","LU0070302665.USD","LU0203347892.USD","LU0310799852.SGD","BK4533","LU2328871848.SGD","LU0320765489.SGD","LU0211326839.USD","LU0320765646.SGD","LU2488822045.USD","LU0256863811.USD","07226","BK4585","BK1161","IE00B1BXHZ80.USD","IE000M9KFDE8.USD","YANG","LU0976567544.SGD","IE00BFXG1179.USD","LU0211326755.USD","BK4516","LU1668664300.SGD","LU","LU1496350502.SGD","01801","BK4504","LU0106831901.USD","LU1267930490.SGD","LU0203345920.USD","LU0211327993.USD","BK1589","LU0211331839.USD","LU1032466523.USD","IE00BWXC8680.SGD","LU0496365809.HKD","HSCEI","LU1244550577.SGD","BK1583","LU1969619763.USD","LU1064131342.USD"],"gpt_icon":0},{"id":"2468122325","title":"信达生物(01801)下跌5.02%，报41.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2468122325","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468122325?lang=zh_cn&edition=full","pubTime":"2024-09-19 13:32","pubTimestamp":1726723977,"startTime":"0","endTime":"0","summary":"9月19日，信达生物(01801)盘中下跌5.02%，截至13:32，报41.6元/股，成交2.74亿元。信达生物主要致力于研发、生产和销售针对肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，已成功上市10个产品，同时有4个品种在审评中，4个新药分子进入III期或关键性临床研究，另有18个新药品种已入临床研究。至2023年10月，其患者援助项目已惠及17余万患者，药物捐赠总价值达34亿人民币。截至2024年中报，信达生物营业总收入39.52亿元、净利润-3.93亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/19133243348416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01801","LU2488822045.USD","LU2328871848.SGD","BK1589","BK1161","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2468517695","title":"信达生物盘中异动 下午盘快速下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468517695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468517695?lang=zh_cn&edition=full","pubTime":"2024-09-19 13:32","pubTimestamp":1726723974,"startTime":"0","endTime":"0","summary":"2024年09月19日下午盘13时32分，信达生物股票出现波动，股价快速跳水5.02%。截至发稿，该股报41.600港元/股，成交量638.924万股，换手率0.39%，振幅7.08%。资金方面，该股资金流入9830.85万港元，流出1.41704亿港元。信达生物股票所在的药品行业中，整体跌幅为0.04%。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091913325598e380d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091913325598e380d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","BK1583","BK1589","LU1969619763.USD","LU2328871848.SGD","01801"],"gpt_icon":0},{"id":"2468317176","title":"信达生物在2024年欧洲肿瘤内科学会（ESMO）大会公布全球首创PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363联合贝伐珠单抗治疗晚期结直肠癌的临床I期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2468317176","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468317176?lang=zh_cn&edition=full","pubTime":"2024-09-18 08:00","pubTimestamp":1726617600,"startTime":"0","endTime":"0","summary":"PD-1/IL-2α-bias双特异性抗体融合蛋白联合贝伐珠单抗治疗晚期结直肠癌的I期临床数据 本次研究数据来自一项I期临床研究，旨在评估IBI363联合贝伐珠单抗治疗晚期结直肠癌受试者的安全性、耐受性和初步有效性。IBI363联合贝伐珠单抗与IBI363单药相比，安全谱类似，未发现新的安全性风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4508243_ZH08243_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2488822045.USD","BK1589","PD","LU2328871848.SGD","BK4023","BK4139","01801","BK1583","BK1161","IVBIY","LU1169590202.USD","LU1169589451.USD","LU1969619763.USD"],"gpt_icon":0},{"id":"2468171753","title":"信达生物在2024年欧洲肿瘤内科学会（ESMO）大会口头报告抗HER2单克隆抗体-喜树碱衍生物偶联物（HER2 ADC）IBI354治疗晚期卵巢癌、乳腺癌等实体瘤的临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2468171753","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468171753?lang=zh_cn&edition=full","pubTime":"2024-09-18 08:00","pubTimestamp":1726617600,"startTime":"0","endTime":"0","summary":"共368例晚期实体瘤受试者接受了不同剂量的IBI354单药治疗，包括178例乳腺癌、92例卵巢癌、38例结直肠癌及60例其他肿瘤的受试者。HER2靶点作为一个成熟靶点，针对HER2的靶向治疗在乳腺癌和胃癌中已被证实具有较好的疗效。已有临床数据提示IBI354在乳腺癌人群具有充分的开发前景。IBI354作为抗HER2单克隆抗体-喜树碱衍生物偶联物，初步研究结果提示在HER2阳性消化系统恶性肿癌观察到积极的疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4508244_ZH08244_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1589","BK4231","BK4139","LU2488822045.USD","BK1161","01801","LU2328871848.SGD","BK4080","BK1583","IVBIY","LU1969619763.USD","ADC"],"gpt_icon":0},{"id":"2468355428","title":"小摩减持信达生物(01801)约1553.61万股 每股作价约43.05港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468355428","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468355428?lang=zh_cn&edition=full","pubTime":"2024-09-17 19:54","pubTimestamp":1726574073,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月11日，小摩减持信达生物(01801)1553.6147万股，每股作价43.0477港元，总金额约为6.69亿港元。减持后最新持股数目约为8780.56万股，最新持股比例为5.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1183897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0976567544.SGD","LU1119994496.HKD","IE00B3S45H60.SGD","LU0267386448.USD","IE000M9KFDE8.USD","IE0034235188.USD","LU0238689110.USD","LU0208291251.USD","IE00BLSP4239.USD","IE00BHPRN162.USD","BK4516","LU1084165304.USD","IE00BWXC8680.SGD","01801","LU0310799852.SGD","BK1589","IE00B1XK9C88.USD","BK1161","LU0234572021.USD","IE00B1BXHZ80.USD","IE00BBT3K403.USD","LU0211326755.USD","IE00BJTD4V19.USD","IE00B775SV38.USD","LU0070302665.USD","IE00BJTD4N35.SGD","LU0203347892.USD","LU","LU1244550494.USD","LU1496350502.SGD","LU0211326839.USD","LU0106831901.USD","LU1261432733.SGD","LU0211327993.USD","LU0320765646.SGD","LU0417517546.SGD","LU2488822045.USD","BK4533","IE00BZ1G4Q59.USD","BK4534","LU1032466523.USD","BK4207","LU0256863811.USD","IE00BLSP4452.SGD","BK4566","LU1969619763.USD","BK4550","LU0211331839.USD","LU1162221912.USD","LU1244550577.SGD"],"gpt_icon":0},{"id":"2468335772","title":"【券商聚焦】汇丰研究升信达生物(01801)目标价5.45% 指上半年收入胜预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2468335772","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468335772?lang=zh_cn&edition=full","pubTime":"2024-09-17 16:47","pubTimestamp":1726562868,"startTime":"0","endTime":"0","summary":"金吾财讯 | 汇丰环球研究发研报指，信达生物(01801)2024至2026年营收将增长28至32%，2025年达到收支平衡。以8倍2024年市销率计算，盈亏平衡临近，加上2024至2025有多项创新药物推出作为催化因素，认为信达生物的估值具有吸引力。该行续指，公司上半年收入胜该行和市场预期，PD-1和IL-2前景良好，可支持业务发展机会，维持“买入”评级，目标价由55港元上调至58港元。该行上调对其2024年至2026年收入预测2至6%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/YzYxNDFlZjgyMzJhODg3YzE4YjBmZGM0MDEyNzIzMzU2NzAy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YzYxNDFlZjgyMzJhODg3YzE4YjBmZGM0MDEyNzIzMzU2NzAy.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1944437","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSBC","01801"],"gpt_icon":0},{"id":"2467862389","title":"汇丰研究升信达生物目标价至58港元 上半年收入胜预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2467862389","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467862389?lang=zh_cn&edition=full","pubTime":"2024-09-16 13:12","pubTimestamp":1726463570,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4207","BK4521","01801","BK1583","LU1169590202.USD","BK4585","HSBC","BK1589","159992","LU2488822045.USD","LU1969619763.USD","BK4023","PD","BK1574","06978","BK1161","LU1169589451.USD","LU2236285917.USD","BK4588","LU2328871848.SGD"],"gpt_icon":0},{"id":"2467689118","title":"《大行》汇丰研究升信达生物(01801.HK)目标价至58元 上半年收入胜预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2467689118","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467689118?lang=zh_cn&edition=full","pubTime":"2024-09-16 10:23","pubTimestamp":1726453380,"startTime":"0","endTime":"0","summary":"汇丰环球研究发表报告指，信达生物(01801.HK) 上半年收入胜该行和市场预期，PD-1和IL-2前景良好，可支持业务发展机会，维持“买入”评级，目标价由55元上调至58元。该行上调对其2024年至2026年收入预测2至6%。汇丰研究预期，信达生物2024至2026年营收将增长28至32%，2025年达到收支平衡。以8倍2024年市销率计算，盈亏平衡临近，加上2024至2025有多项创新药物推出作为催化因素，认为信达生物的估值具有吸引力。(ha/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-09-13 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20181016155302092_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20181016155302092_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1381551/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01801"],"gpt_icon":0},{"id":"2467009118","title":"信达生物(1801.HK)：亮相ESMO&WCLC大会 PD-1&IL2Α疗效出色","url":"https://stock-news.laohu8.com/highlight/detail?id=2467009118","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467009118?lang=zh_cn&edition=full","pubTime":"2024-09-14 00:00","pubTimestamp":1726243200,"startTime":"0","endTime":"0","summary":"核心观点公司分别在WCLC 和ESMO 大会上更新IBI363 在NSCLC 和CRC 上的疗效数据。事件9 月9 日，信达生物在IBI363在ESMO 大会上公布I 期结直肠癌数据。IBI363 在IO 经治的晚期肺鳞癌患者中展现突破性疗效。IBI363 在PD-L1 低表达人群中展现突出疗效。同时，IBI363 整体安全性优异，≥ 3级的TEAEs 发生率为17.1%，仅一例患者因副作用停止治疗。我们预计信达生物2024-2026 年收入为78.0 亿元、113.8 亿元和148.7 亿元，采用 DCF 估值，公司合理市值为 1120 亿港元，维持目标价至69.01 港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091419311895653a1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091419311895653a1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","01801","BK1161","BK1589","BK1583","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2467128917","title":"信达生物(01801)上涨2.44%，报44.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2467128917","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467128917?lang=zh_cn&edition=full","pubTime":"2024-09-13 15:53","pubTimestamp":1726214017,"startTime":"0","endTime":"0","summary":"9月13日，信达生物(01801)盘中上涨2.44%，截至15:53，报44.0元/股，成交3.0亿元。信达生物主要致力于研发、生产和销售针对肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，已成功上市10个产品，同时有4个品种在审评中，4个新药分子进入III期或关键性临床研究，另有18个新药品种已入临床研究。至2023年10月，其患者援助项目已惠及17余万患者，药物捐赠总价值达34亿人民币。截至2024年中报，信达生物营业总收入39.52亿元、净利润-3.93亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/13155343250153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1589","LU2488822045.USD","BK1161","01801","LU2328871848.SGD","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2467762060","title":"医药创新支持力度加大 创新药板块集体上行 中国生物制药(01177)涨4.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467762060","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467762060?lang=zh_cn&edition=full","pubTime":"2024-09-13 11:02","pubTimestamp":1726196570,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块集体上行，来凯医药 涨6.07%，中国生物制药涨4.5%，金斯瑞生物科技涨4.07%，和黄医药涨2.68%，信达生物涨2.1%。对国家重点支持的创新药品和医疗器械，在审评审批、检验核查等方面加强服务指导，引导企业坚持以临床价值为导向，以患者为中心制定研发策略。提升创新药品和医疗器械的可及性，积极支持创新药械进医院、进医保。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ZDVjZjI4MzkxNjI4NTkwMDQ5NTQ5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDVjZjI4MzkxNjI4NTkwMDQ5NTQ5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1944232","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","BK1576","01801","HK0000320264.USD","LU1969619763.USD","159992","BK1161","159938","HK0000320223.HKD","01548","BK1587","BK1141","BK1515","01177","BK1521","02105","BK1589","00013","LU2328871848.SGD","BK1574","BK1588","BK1583","HK0000306685.HKD","LU2488822045.USD","06978","09939","BK1191"],"gpt_icon":0},{"id":"2466290388","title":"花旗：对信达生物开启90天上行催化剂观察期 目标价62港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2466290388","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466290388?lang=zh_cn&edition=full","pubTime":"2024-09-12 10:24","pubTimestamp":1726107840,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 花旗发布研究报告称，对信达生物（01801）开启90天上行催化剂观察期。该行预期，在新产品的带动下，信达生物强劲的增长势头将会持续。taletrectinib（ROS1）/Mazdutide/IBI311 （IGF-1R）/IBI112 （IL-23 p19）预期于下半年或明年料获批。目标价62港元，评级“买入/高风险”。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：史丽君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2024-09-12/doc-incnwewu6636582.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2024-09-12/doc-incnwewu6636582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01801"],"gpt_icon":0},{"id":"2466940042","title":"信达生物现涨超4% 玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2466940042","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466940042?lang=zh_cn&edition=full","pubTime":"2024-09-12 10:00","pubTimestamp":1726106453,"startTime":"0","endTime":"0","summary":"信达生物早盘上涨4.16%，现报45.10港元，成交额1.24亿港元。 信达生物今日宣布，胰高血糖素样肽-1受体/胰高血糖素受体双重激动剂玛仕度肽在中国2型糖尿病受试者开展的III期临床研究的主要研究结果在第60届欧洲糖尿病研究协会年会中以重磅进展口头报告的形式披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-09-12/doc-incnwewu6627461.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-09-12/doc-incnwewu6627461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["LU2328871848.SGD","BK1161","BK1589","01801","LU2488822045.USD","LU1969619763.USD","BK1583"],"gpt_icon":0},{"id":"2466292157","title":"生物制药板块走势强劲 科伦博泰生物(06990)涨6.6% 机构指创新药企业盈亏平衡点渐近","url":"https://stock-news.laohu8.com/highlight/detail?id=2466292157","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466292157?lang=zh_cn&edition=full","pubTime":"2024-09-12 09:54","pubTimestamp":1726106083,"startTime":"0","endTime":"0","summary":"分板块来看，表现最好的是创新药，收入平均增长25.3%，主要由于创新药享受较为积极的医保支付环境，以及部分创新药企业实现了品种出海授权，获得授权收入。大部分Biotech企业仍处于亏损状态。目前国内Biotech已进入商业化放量兑现期，人均单产持续提升。在重磅创新药产品强劲销售增长，费用增速放缓的共同带动下，头部Biotech企业的盈亏平衡点渐近，有望未来1-3年扭亏后，利润快速释放。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/NDQ5NWNkMjllM2EwMmIxOTk5NDIxODc2Mzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/NDQ5NWNkMjllM2EwMmIxOTk5NDIxODc2Mzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1944135","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1583","LU0196878994.USD","BK1574","LU2488822045.USD","06990","BK1589","06978","00013","01801","LU2328871848.SGD","BK1191","LU1969619763.USD","159992","BK1588","BK1161","02162"],"gpt_icon":0},{"id":"2466729490","title":"港股异动 | 信达生物(01801)涨超4% 玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2466729490","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466729490?lang=zh_cn&edition=full","pubTime":"2024-09-12 09:48","pubTimestamp":1726105701,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物涨超4%，截至发稿，涨4.16%，报45港元，成交额7161.95万港元。消息面上，信达生物今日宣布，胰高血糖素样肽-1受体/胰高血糖素受体双重激动剂玛仕度肽在中国2型糖尿病受试者开展的III期临床研究的主要研究结果在第60届欧洲糖尿病研究协会年会中以重磅进展口头报告的形式披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1182288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","LU2488822045.USD","LU2328871848.SGD","BK1589","BK1161","BK1583","LU1969619763.USD","BK4134","III"],"gpt_icon":0},{"id":"2466921662","title":"花旗：对信达生物(01801)开启90天上行催化剂观察期 目标价62港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2466921662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466921662?lang=zh_cn&edition=full","pubTime":"2024-09-12 09:48","pubTimestamp":1726105681,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研究报告称，对信达生物(01801)开启90天上行催化剂观察期。该行预期，在新产品的带动下，信达生物强劲的增长势头将会持续。taletrectinib (ROS1)/Mazdutide/IBI311 (IGF-1R)/IBI112 (IL-23 p19)预期于下半年或明年料获批。目标价62港元，评级“买入/高风险”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1182290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801"],"gpt_icon":0},{"id":"2466024299","title":"《大行》花旗对信达生物(01801.HK)开启90天上行催化剂观察期","url":"https://stock-news.laohu8.com/highlight/detail?id=2466024299","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466024299?lang=zh_cn&edition=full","pubTime":"2024-09-12 09:15","pubTimestamp":1726103700,"startTime":"0","endTime":"0","summary":"花旗发表报告，对信达生物(01801.HK) 开启90天上行催化剂观察期。该行预期，在新产品的带动下，信达生物强劲的增长势头将会持续。taletrectinib (ROS1)/Mazdutide/IBI311 (IGF-1R)/ IBI112 (IL-23 p19)预期于下半年或明年料获批。目标价62元，评级“买入/高风险”。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-09-11 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190319115557208_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190319115557208_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1380855/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","LU2328871848.SGD","LU1969619763.USD","BK1161","LU2488822045.USD","01801","BK1589"],"gpt_icon":0},{"id":"2466293608","title":"头对头优效于高剂量度拉糖肽，玛仕度肽糖尿病III期临床研究DREAMS-2结果于EASD口头重磅报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2466293608","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466293608?lang=zh_cn&edition=full","pubTime":"2024-09-12 08:00","pubTimestamp":1726099200,"startTime":"0","endTime":"0","summary":"同时，玛仕度肽首个减重三期临床GLORY-1研究结果也于本次大会作口头汇报。整体安全性特征与玛仕度肽既往临床研究一致，未发现新增安全性信号。玛仕度肽对比度拉糖肽联合口服降糖药治疗在中国2型糖尿病受试者的3期研究取得成功，其结果在今年EASD大会以口头报告披露，证明了玛仕度肽在血糖控制、减重以及多种代谢指标方面的综合获益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4503608_ZH03608_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2488822045.USD","BK1589","III","BK4139","01801","BK4134","BK1583","BK1161","IVBIY","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0367},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.1481},{"period":"6month","weight":0.1496},{"period":"1year","weight":0.0991},{"period":"ytd","weight":0.0246}],"compareEarnings":[{"period":"1week","weight":0.0247},{"period":"1month","weight":0.0132},{"period":"3month","weight":-0.0418},{"period":"6month","weight":0.0473},{"period":"1year","weight":-0.0151},{"period":"ytd","weight":0.0359}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销，以及提供咨询及研发服务。该公司的主要产品为达伯舒（信迪利单抗注射液），用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303，用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305，用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌（NSCLC）。利妥昔单抗生物类似药IBI-301，用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.049204},{"month":2,"riseRate":0.666667,"avgChangeRate":0.101831},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050735},{"month":4,"riseRate":0.666667,"avgChangeRate":0.022046},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006538},{"month":6,"riseRate":0.666667,"avgChangeRate":0.118103},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.029935},{"month":8,"riseRate":0.833333,"avgChangeRate":0.002206},{"month":9,"riseRate":0.666667,"avgChangeRate":0.025364},{"month":10,"riseRate":0.4,"avgChangeRate":0.043974},{"month":11,"riseRate":0.5,"avgChangeRate":0.068539},{"month":12,"riseRate":0.5,"avgChangeRate":0.07208}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}